Table II.
Significantly expanded TCR Vβ–expressing cells after HSCT
| Patient | T subset | TCR | Pre-Txa | 6 mo after Tx |
1 yr after Tx |
2 yr after Tx |
|---|---|---|---|---|---|---|
| 1 | CD4+ | BV1 | 2.5 | 8.8b | ND | 3.5 |
| CD4+ | BV17 | 10.5 | 32.0 | ND | 9.3 | |
| 2 | CD8+ | BV18 | 0.5 | 6.1 | 2.2 | 2.0 |
| CD8+ | BV20 | 2.6 | 7.6 | 8.1 | 9.4 | |
| 4 | CD8+ | BV1 | 5.7 | 4.2 | 15.6 | 9.8 |
| 5 | CD8+ | BV8 | 6.9 | 17.9 | 14.0 | 18.9 |
| CD8+ | BV21.3 | 1.4 | 3.6 | 2.9 | 6.6 | |
| 6 | CD8+ | BV1 | 5.2 | ND | 17.5 | 9.9 |
| CD8+ | BV5.1 | 3.5 | ND | 8.6 | 9.4 | |
| 7 | CD8+ | BV5.1 | 1.75 | 6.8 | 4.7 | ND |
| CD8+ | BV23 | 0.3 | 49.9 | 53.9 | ND |
a
Tx, treatment.
b
Bold numbers indicate a significant expansion according to the criteria described in Materials and methods.